A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients.
Moreno G, Ruiz-Botella M, Martín-Loeches I, Gómez Álvarez J, Jiménez Herrera M, Bodí M, Armestar F, Marques Parra A, Estella Á, Trefler S, Jorge García R, Murcia Paya J, Vidal Cortes P, Díaz E, Ferrer R, Albaya-Moreno A, Socias-Crespi L, Bonell Goytisolo JM, Sancho Chinesta S, Loza A, Forcelledo Espina L, Pozo Laderas JC, deAlba-Aparicio M, Sánchez Montori L, Vallverdú Perapoch I, Hidalgo V, Fraile Gutiérrez V, Casamitjana Ortega AM, Martín Serrano F, Nieto M, Blasco Cortes M, Marín-Corral J, Solé-Violán J, Rodríguez A; on behalf COVID-19 SEMICYUC Working Group.
Moreno G, et al. Among authors: albaya moreno a.
Med Intensiva (Engl Ed). 2023 Jan;47(1):23-33. doi: 10.1016/j.medine.2021.10.016. Epub 2022 Oct 19.
Med Intensiva (Engl Ed). 2023.
PMID: 36272908
Free PMC article.